RESUMO
Hemorrhagic cystitis (HC) is considered a fatal complication of cyclophosphamide (CP). Down-regulation of Nrf2 and induction of pro-inflammatory mediators are the main pathological factors. Recently, ameliorative potential of the angiotensin II (AII) type-1 (AT1) receptor blocker olmesartan (OLM) on oxidative stress and inflammatory cytokines was reported. The current study aims to investigate the possible protective effect of OLM on CP-induced HC in Wistar rats. The animals were divided into the control group (0.5% W/V carboxymethylcellulose, p.o.); OLM group (20 mg/kg, p.o., for 21 days); CP group (a single dose of 100 mg/kg, i.p.); and the remaining groups that received CP i.p. with oral OLM 5, 10 and 20 mg/kg for 21 days, respectively. The bladder tissue was collected for histopathology, immunohistochemistry, ELISA, Western blot, and oxidative stress assay. The OLM at doses of 10 and 20 mg/kg attenuated increase in TNF-α, IL-6, NF-kB, iNOS, and COX-2 induced by CP. Additionally, it up-regulated the Nrf2/HO-1 pathway, bladder GSH content, and CAT and SOD activities. The data indicated that OLM inhibited ROS-induced NF-kB, which caused inhibition of pro-inflammatory cytokines and activation of the Nrf2/HO-1 pathway. Hence, OLM holds great promise for preventing CP-induced HC.
Assuntos
Cistite , Fator 2 Relacionado a NF-E2 , Angiotensina II/metabolismo , Animais , Carboximetilcelulose Sódica , Ciclo-Oxigenase 2 , Ciclofosfamida/toxicidade , Cistite/induzido quimicamente , Cistite/tratamento farmacológico , Cistite/patologia , Citocinas/metabolismo , Heme Oxigenase (Desciclizante)/metabolismo , Imidazóis , Mediadores da Inflamação/metabolismo , Interleucina-6/farmacologia , NF-kappa B/metabolismo , Estresse Oxidativo , Ratos , Ratos Wistar , Espécies Reativas de Oxigênio , Transdução de Sinais , Superóxido Dismutase/metabolismo , Tetrazóis , Fator de Necrose Tumoral alfa/metabolismoRESUMO
AIMS: Consumption of nutraceuticals without enough data regarding their interactions has raised safety concerns. Importantly, consumption of some natural-products in health-compromised conditions has caused liver injury due to the evolved pro-oxidant load. This study evaluates the safety of quercetin (QUR), as an extensively-used flavonoid owing to its antioxidant and hepatoprotective activities, in normal- and lipopolysaccharides (LPS)-primed livers, and to investigate the influence of the LPS-induced mild inflammatory/febrile condition on QUR effects. MAIN METHODS: For liver priming, a non-injurious LPS dose that mediates limited inflammation/mild fever was chosen. Selection of QUR dose/duration of treatment, for a coherent combination-regimen, was also adopted. Single LPS i.p injection (1.5 mg/kg)/oral QUR (20 mg/kg/day, IG) for 5-days was the optimal regimen for the combination group. On day-6, serum ALT/AST/ALP levels were measured, as liver-damage biomarkers. Hepatic; MDA/GSH were determined, as oxidative-stress measures, Bcl-2/cleaved-caspase-3 were assessed as apoptosis biomarkers, IL-6 expression/NF-κB/Nrf-2 immunoreactivities were evaluated as regulators for inflammation. KEY FINDINGS: Exaggerated hepatic injury was seen upon QUR treatment in LPS-presensitized mice; as evidenced by liver histopathological degeneration, which was confirmed by biochemical elevations of serum AST/ALT/ALP, along with oxidant-burden increase (↑MDA/↓GSH) and molecular augmentation of inflammation (NF-κB/IL-6 activation) that led to enhancement of proapoptotic signaling (caspase-3 activation/Bcl-2 inhibition). Such events were accompanied by potentiation of endogenous anti-inflammatory/antioxidant response (↑ hepatic Nrf-2). SIGNIFICANCE: The study highlights caution when QUR is consumed in health-compromised conditions, by revealing the role of fever/mild inflammation in enhancing liver toxicity upon QUR utilization, which was not apparent with moderate consumption of QUR-alone.